On May 31, 2018 TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer and wet age-related macular degeneration, reported that Charles Theuer, M.D., Ph.D., President and CEO, will present at the Jefferies 2018 Healthcare Conference at 12:30 pm EDT on Friday, June 8, 2018, in New York, NY (Press release, Tracon Pharmaceuticals, MAY 31, 2018, View Source [SID1234527008]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To access a live webcast of the presentation, please visit the "Events and Presentation" page within the "Investors" section of the TRACON Pharmaceuticals website at www.traconpharma.com. A replay of the webcast will be available on the website for 60 days following the event.

On May 31, 2018 Five Prime Therapeutics, Inc. (Nasdaq: FPRX), a biotechnology company discovering and developing innovative immuno-oncology protein therapeutics, reported that Francis Sarena, Chief Strategy Officer, will present at the Jefferies 2018 Global Healthcare Conference, June 7, 2018, at 11:00 am ET (Press release, Five Prime Therapeutics, MAY 31, 2018, View Source [SID1234526992]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation will be webcast and may be accessed at the "Events & Presentations" section of the Company’s website at View Source Five Prime will maintain an archived replay of the webcast on its website for 30 days after the conference.

On May 31, 2018 Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, reported that company management will present at two upcoming conferences (Press release, Xencor, MAY 31, 2018, View Source [SID1234527009]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Jefferies 2018 Healthcare Conference
Date: Thursday, June 7, 2018
Time: 1:30 p.m. ET
Location: New York, NY

JMP Securities Life Sciences Conference
Date: Wednesday, June 20, 2018
Time: 1:30 p.m. ET
Location: New York, NY

Live webcasts of both events will be available under "Events & Presentations" in the Investors section of the Company’s website located at View Source A replay of the presentations will be posted on the Xencor website approximately one hour after the live events and will be available for 90 days following the presentations.

On May 31, 2018 Nordic Nanovector ASA (OSE: NANO) reported that it will present a poster describing a preclinical analysis of genetic factors that correlate with the responsiveness of non-Hodgkin’s lymphoma (NHL) cell lines to Betalutin (177Lu-lilotomab satetraxetan) at the 23rd annual meeting of the European Hematology Association (EHA) (Free EHA Whitepaper) (Stockholm, Sweden, 14-17 June) (Press release, Nordic Nanovector, MAY 31, 2018, View Source [SID1234553501]). This preclinical study highlights the generally promising activity of Betalutin against diffuse large B-cell lymphoma (DLBCL) cell lines.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The abstract is available online (click here) and the poster will be available on the company’s website at: www.nordicnanovector.com following the presentation on 15 June.

Poster details

Abstract PF642

Abstract title: Systems biology analysis of responsiveness of non-Hodgkin lymphoma B-cell lines to CD37 targeting radioimmunotherapy

Authors: Melhus, KB et al.

Date: Friday 15 June

Time: 17:30-19:00 (CEST)

On May 31, 2018 GTx, Inc. (Nasdaq: GTXI) reported that Robert J. Wills, PhD, Executive Chairman, will present a company overview at the Jefferies 2018 Global Healthcare Conference on Thursday, June 7, 2018 at 10:00 am ET in New York (Press release, GTx, MAY 31, 2018, View Source;p=RssLanding&cat=news&id=2352457 [SID1234526993]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A simultaneous webcast of the presentation can be accessed by visiting the investor relations section of the GTx website at View Source A replay of the presentation will also be available and archived on the site for 30 days.